According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, and the benefit-risk profile of the vaccine remains positive for all ...

Disadvantaged communities need society’s absolute best leaders in their schools. This charity ensures they get them ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...

Moderna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 ...

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Amgen today and set a price target of $330.00. The company’s shares opened today at $298.51. Elevate Your Invest ...

RFK Jr. cancels U.S. Preventive Services Task Force meeting; the Department of Health and Human Services backtracked on its claim that it would release ethics forms for new members of the Advisory ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

The court determined that Pfizer (NYSE: PFE) and BioNTech’s (NASDAQ: BNTX) Comirnaty vaccine had infringed on this patent, making Moderna eligible for damages for sales after March 2022. In the same ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...